BACKGROUND Treatment of cytomegalovirus (CMV) infections after stem cell transplantation (SCT) does not always lead to a rapid viral response. The causes of treatment failure may be either viral resistance or immunological failure to control viral replication. This study investigated the response to pre-emptive treatment in CMV infections in order to define risk factors for treatment failure, i...

BACKGROUND Limited information about tumor status and the time at which antiviral therapy was initiated may have influenced effect estimation in previous research. The aim of this study was to investigate the effect of antiviral therapies on HBV-related HCC progression and deaths in patients receiving curative treatment based on clear clinical-pathological cancer status and the association of s...

  Following the skyrocketing spread of SARS-CoV-2 into almost all the countries over five continents, diverse clinical strategies are urgently needed to defeat its pandemic, considering that an magic-bullet antiviral vaccine or treatment is presently unavailable. WHO later proclaimed the viral outbreak as a pandemic. Despite this fast speed of the pandemic, any recommended treatment must first...

The launch of first-generation protease inhibitors (PIs) is a major step forward in HCV treatment. However, the major advance is up to now restricted to genotype 1 (GT-1) patients. The development of second-wave and second-generation PIs yields higher antiviral potency through plurigenotypic activity, more convenient daily administration, fewer side effects and, for the second-generation PIs, p...

An updated review of the antiviral agents currently available or under trial for the treatment of chronic hepatitis B is presented. There are two broad groups: (1) immunomodulators including interferon a (which also has a direct antiviral effect), thymosin a1 and Theradigm-HBV and (2) viral suppressors such as famciclovir and lamivudine. These agents are still in clinical trial worldwide, singl...

PURPOSE OF REVIEW Long-acting antiretroviral (ARV) agents are currently under development for the treatment of chronic HIV infection. This review focuses on data recently produced on injectable ARVs for patients living with HIV/AIDS and on the patients' perspectives on the use of these agents. RECENT FINDINGS Crystalline nanoparticle formulations of the nonnucleoside reverse transcriptase inh...

The link between chronic hepatitis C virus (HCV) infection and a subset of B-cell non-Hodgkin lymphomas (B-NHL) is strongly supported by epidemiological studies. Evidence demonstrating complete regression of lymphoma after antiviral treatments suggests possible chronic antigenic stimulation for the origin of B-NHL and provides evidence for a virus-mediated lymphomagenesis. B-NHL is a heterogene...

Purpose Antiviral drugs are standard treatment for chronic hepatitis B. In traditional Chinese medicine practice, administration of drugs through acupuncture point (acupoint) is considered better than intramuscular injection or intravenous infusion. In this review, we evaluated comparative effects and safety of antiviral drugs through acupoint injection versus other administration for treatment...

BACKGROUND Chronic hepatitis B and C infections represent major risk factors for the development of hepatocellular carcinoma (HCC). Recently, the management of patients with viral hepatitis has dramatically changed. In the present review we discuss the impact of these developments on the prevention of HCC as well as the treatment of patients with HCC. METHODS Studies indexed in Medline betwee...

Of 13 patients with chickenpox pneumonia (12 of them adults) treated during 1979-87, 10 received antiviral drugs--nine acyclovir and one vidarabine. Three died despite intensive treatment. Serious secondary infections occurred in six cases. There were no clear indications that antiviral treatment altered the natural history of the condition. Acyclovir may at present be used too late in the cour...